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Detection of circulating tumor cells in the peripheral blood
of patients with androgen-independent, advanced or
metastatic prostate cancer
To the Editor: The presence of circulating tumor cells (CTC) in the peripheral
blood of cancer patients has attracted a great deal of attention among
investigators. The clinical significance of CTC has probably best been
established in breast cancer, where it has been shown that the detection of
CTC in metastatic patients correlates with early clinical relapse and patient
death [1]. Gene expression profiling of CTC has been extended to other
metastatic cancers including colorectal and prostate cancer [2,3].
Recently, a porous barrier density-gradient centrifugation system was
developed that allows for enrichment of CTC from peripheral blood [4]. When
coupled with the use of specific genes for real-time reverse transcriptase (RT)-
polymerase chain reaction (PCR), the buoyant density separation approach
has the potential to increase sensitivity and specificity of CTC detection. We
have previously utilized this system in combination with multi-marker real-time
RT-PCR in a pilot study involving Stage IV breast cancer patients at the
Medical University of South Carolina (MUSC). We detected breast cancer-
associated overexpression in the peripheral blood of 13 out of 20 (65%)
patients [5]. We also extended these observations to nonsmall cell lung cancer
as 60% of patients with this tumor exhibited multimarker overexpression in
their peripheral blood [6].
We enrolled 15 patients (11/15 of African-American ancestry) with advanced
or metastatic AIPC in a clinical study sponsored by the General Clinical
Research Center (GCRC) at the MUSC. The main objective of the study was
to measure, by real-time, reverse transcriptase (RT)-polymerase chain
reaction (PCR), the expression of a specific set of genes (EpCAM1, EpCAM2,
XAG, S100P, DAG1, Claudin7, Ese1, Mal2, Spint2, ERG, and ETV1) in the
peripheral blood of enrolled patients.
Results from 11 out of 15 enrolled patients could be analyzed and we found
evidence of CTC in 8 of 11 subjects (6 of 8 for African–Americans). EpCAM1
and EpCAM2 were the most informative markers (Fig. 1). To the best of our
knowledge, this is the first report identifying EpCAM2 as a marker for CTC in
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Causes and diagnosis of copper deficiency
To the Editor: I found the article by Huff et al. [1] on copper deficiency and
myelodysplasia interesting and useful, but as a long time copper metabolism
worker I found two problems in this article. First, copper deficiency was
unexplained in three cases. The authors are aware of zinc ingestion as a
cause of copper deficiency, and there is also the syndrome on which we have
published [2] of unexplained high circulating zinc levels causing copper
deficiency. Yet the authors do not mention questioning the patients about zinc
intake, nor did they apparently measure serum or urine zinc. It is quite possible
that one or more of the unexplained cases could be explained by a zinc
mechanism.
The second problem has to do with the authors’ lack of certainty on how to
diagnose copper deficiency, for example their statement, \How to diagnose
copper deficiency is not entirely clear." In their subsequent analysis of this
area, they completely ignore a body of literature built up by our group on just
that question. In our work, we induce mild copper deficiency with
tetrathiomolybdate to achieve therapeutic objectives (reduction in angiogen-
Figure 1. Expression levels for EpCAM2 (left panel), and
EpCAM1 (right panel) measured by real-time RT-PCR. The
denominators of fractions at the bottom of each panel
refer to the number of subjects tested: 19 controls (full tri-
angles), 11 prostate cancers (diamonds). The numerators
refer to the number of subjects overexpressing EpCAM2
(left panel) or EpCAM1 (right panel) in controls (0 and 0),
and prostate cancers (7 and 5), respectively. The full dia-
mond refers to the only patient positive for EpCAM1 and
negative for EpCAM2, barely below the threshold of signif-
icance. Note also that most control subjects show no
detectable expression of EpCAM1 (16 of 19 subjects) or
EpCAM2 (18 of 19 subjects). [Color figure can be viewed
in the online issue, which is available at www.interscience.
wiley.com.]
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esis for cancer therapy, reduction in fibrosis, reduction in inflammation,
treatment of autoimmune diseases) and have published on both clinical and
animal model studies extensively (for reviews, see Refs. 3–6). We have
established that the ceruloplasmin level is an excellent surrogate marker of
copper status, and the various factors that can elevate ceruloplasmin levels,
such as inflammatory disease, hormone therapy, etc., do not interfere with this
use. The ceruloplasmin levels will come down in copper deficiency in all cases.
Thus, using ceruloplasmin levels, rather than serum copper, is by far the best
way to detect copper deficiency.
GEORGE J. BREWER
Department of Human Genetics and Department of Internal
Medicine, University of Michigan Medical School
Ann Arbor, Michigan
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First factor IX mutations in Albanian hemophilia
B patients
To the Editor: Hemophilia B is an X-linked bleeding disorder, caused by
deficient or defective factor IX (FIX) [1]. FIX is a vitamin K-dependent single-
chain serine protease composed of 415 amino acids encoded by F9, which
spans about 34 kilobases and contains 8 exons [1]. Among the 2,891 patients
with hemophilia B listed in the 2004 updated database, 962 show unique
molecular events (http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html).
Furthermore, 91 goss deletions or insertions have been also identified.
Within the framework of the Twinning Program of the World Federation of
Hemophilia, and working between the Hemophilia Centers of Vicenza (Italy)
and Tirana (Albania), we assessed the genetic basis of hemophilia B in seven
patients with hemophilia B from five families (Table I). Patients HBA-1 and 2
were brothers, while HBA-5 and 6 were cousins. Apart from HBA-7, all have
severe disease (FIX < 1%).
Coding regions and intron/exon boundaries of the F9 were PCR-amplified in
nine reactions (methods available upon request) and the amplified fragments
were sequenced on an ABI Prism 310 Genetic Analyser. All sequence
changes were confirmed in both DNA strands and sought in 200 chromo-
somes.
A gross gene deletion spanning exons 1–6 was identified in the two brothers
HBA-1 and HBA-2 and in their mother. This deletion occurred also in a
Swedish [2] and an American patient, both without inhibitor, and in an Italian
patient with inhibitor [3]. Thus, this type of deletion is likely to occur
independently from a founder effect. Patient HBA-1 had allergic reactions
upon treatment with FIX concentrates and at the time of sampling a modest
inhibitor titer was present (0.9 BU), while no inhibitor was present in the
brother. Two splicing defects (IVS1 + 2, nt. 119T > C and IVS2 + 2, nt. 6491T >
C, novel) were also detected in association with a severe phenotype. In silico
analysis by the splice site prediction program (http://fruitfly.orh/cgi-bin/seq-
tools/splice.pl) of the novel IVS2 + 2 nt. 6491T > C predicts the loss of the
original donor splice site, since the original probability score of 0.97 became
nil after introducing the base exchange. The missense mutation Gly234Ser
detected in patients HBA-5 and 6 was previously identified in an Italian patient
with a severe phenotype [3]. Two additional patients, one French and one
Italian [3], with Gly234Arg mutation and a severe phenotype have been
reported, emphasizing the physiologic relevance of Gly234. A novel missense
mutation (30953C > A; Pro278Thr) was identified in exon 8 in a patient with
mild deficiency and also in his mother. In the database, only a different
mutation in an UK patient with 30954C > A change (Pro278His) and a FIX level
of 30% has been reported at the same codon. The Pro to Thr change occurs
between an amino acid with a secondary amino group and a hydrophilic amino
acid, with a hydroxyl group being introduced. Despite this apparently
significant amino acid change, the mild laboratory and clinical phenotype
suggests that although Pro278 is in the catalytic region, it is not drastically
relevant to FIX activity. Both Gly234Ser and Pro278Thr changes occur at
highly conserved amino acids, as demonstrated in murine, canine, and simian
FIX (http://www.ncbi.nih.gov/blast/).
In conclusion, we have identified the first mutations (two novel) in Albanian
hemophilia B patients. These results will help in establishing the Albanian
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TABLE I. Mutations in Albanian Hemophilia B Patients
Patient Nucleotide position Amino acid change FIX:C (%) Exons Comments
HBA-1 Exon 1–6 deletion – <1 1–6 Inhibitor
HBA-2 Exon 1–6 deletion – <1 1–6
HBA-3 119T > C IVS1 + 2 – <1 INTRON 1 Splicing mutation
HBA-4 6491T > C IVS2 + 2 – <1 INTRON 2 Splicing mutation, Novel
HBA-5 30153G > A Gly234Ser <1 7
HBA-6 30153G > A Gly234Ser <1 7
HBA-7 30953C > A Pro278Thr 12 8 Novel
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